Navigation Links
Depression associated with poor medication adherence in patients with chronic illnesses
Date:5/10/2011

People who are depressed are less likely to adhere to medications for their chronic health problems than patients who are not depressed, putting them at increased risk of poor health, according to a new RAND Corporation study.

Researchers found that depressed patients across a wide array of chronic illnesses such as diabetes and heart disease had 76 percent greater odds of being non-adherent with their medications compared to patients who were not depressed. The findings were published online by the Journal of General Internal Medicine.

The study is the largest systematic review to date to look at the role that depression plays in medication adherence among patients in the United States.

"These findings provide the best evidence to date that depression is an important risk factor that may influence whether patients adhere to their medications," said Dr. Walid F. Gellad, the study's senior author and a natural scientist at RAND, a nonprofit research organization. "There are important implications for both patient health and for health care costs.

"Doctors and other providers should periodically ask patients with depression about medication adherence. Also, when treating a patient who is not taking their medication correctly, they should consider the possibility that depression is contributing to the problem."

Poor adherence to prescribed medication is a well-known problem that is associated with higher death rates among people with chronic illnesses. It is also blamed for increasing U.S. health care costs.

Researchers from RAND and the Claremont Graduate School conducted the study by examining past studies that have measured medication adherence. They combined information from 31 studies involving more than 18,000 people -- significantly more than past reviews to examine the link between medication adherence and depression.

The study is the first to review the association between depression and medication adherence for patients with high blood pressure and high cholesterol. Other conditions examined in the study include coronary heart disease, diabetes and asthma. The link between depression and medication adherence did not vary significantly between the different chronic illnesses, said Gellad, who is also a physician with the VA Pittsburgh Healthcare System.

"The consistent link between depression and nonadherence across all these illnesses underscores the seriousness of the role that depression plays in keeping people from properly managing chronic conditions," said Jerry L. Grenard, the study's lead author and an assistant professor at the Claremont Graduate School. "That consistency also suggests that lessons learned about how to improve medication adherence among depressed patients with one disease may be applied to other chronic conditions."

Researchers say that depression is just one barrier to getting patients to follow medication recommendations. Additional well-documented barriers to medication adherence are dose complexity and patient cost-sharing. Other barriers that may play a role include beliefs about medications, social support, side effects and provider factors.


'/>"/>

Contact: Warren Robak
robak@rand.org
310-451-6913
RAND Corporation
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. Husbands hostile, anti-social behaviors increase wives symptoms of depression, researchers find
3. Acupuncture May Ease Depression During Pregnancy
4. Belief in a caring god improves response to medical treatment for depression
5. Stress hormone, depression trigger obesity in girls
6. Psychiatrys main method to prevent mistaken diagnoses of depression doesnt work: NYU study
7. Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center
8. Video games may help combat depression in older adults
9. Obesity and Depression: A Vicious Circle?
10. Major depression more than doubles risk of dementia among adults with diabetes
11. Study shows phyical therapy exercise program can reduce risk of postnatal depression in new mothers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... 08, 2016 , ... Healthcare is in flux. The GOP ... the mass media launching of story movements to highlight what's most unfair about ... experiences; such a movement can generate the network power to improve healthcare policies ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016   TriNetX , the health research ... signed a membership agreement to join the ... new cures. The TriNetX network is ... patients globally, biopharmaceutical companies and contract research organizations ... design, site selection, patient recruitment, and collaborative research ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
Breaking Medicine Technology: